CSL Limited

Equities

CSL

AU000000CSL8

Pharmaceuticals

Market Closed - Australian S.E. 02:10:45 2024-04-19 am EDT 5-day change 1st Jan Change
269.5 AUD -0.70% Intraday chart for CSL Limited -3.89% -5.99%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Vifor Pharma offers to rectify anti-competitive behaviour against rival RE
Miners boost Australian shares; NZ cenbank keeps rates steady RE
New Zealand shares hold gains as c.bank expectedly holds rate; Aussie shares up RE
Australian shares rise on mining and healthcare boost; US CPI data, RBNZ in focus RE
Australian shares end higher as miners surge; US CPI in focus RE
Australian shares fall as financials and healthcare stocks drag RE
Australian shares hit record high; RBA cautious on inflation RE
Australian shares inch higher; inflation data reinforces subdued rate-cut view RE
CSL Prices $1.25 Billion Corporate Bonds Offering MT
Miners, healthcare firms push Australia stocks higher RE
Australian shares fall as miners, banks weigh RE
Banks drive Australian shares to record high on firming rate-cut bets RE
CSL Seqirus Confirms Full Preparation to Implement the Fda's Vaccines and Related Biological Products Advisory Committee CI
Morgan Stanley Adjusts CSL’s Price Target to AU$310 From AU$318, Keeps at Overweight MT
Australia Health Stocks to Remain at Premium to ASX200, Morgan Stanley Says MT
Australian shares skid off record highs to end lower; GDP data awaited RE
Australian shares end marginally up as energy, financials offset weak miners RE
Australian shares inch lower as banks offset commodity gains RE
Jarden Research CSL’s Price Target to AU$296.02 From AU$298.57, Keeps at Overweight MT
Australian shares end slightly lower; US inflation data on tap RE
Jarden Research Adjusts CSL’s Price Target to AU$298.57 From AU$316.16, Keeps at Overweight MT
Australian shares flat as CSL counters gains in banks, miners RE
CSL Limited Reaffirms Group Earnings Guidance for the Fiscal Year 2024 CI
Transcript : CSL Limited, H1 2024 Earnings Call, Feb 13, 2024
CSL Ltd. Posts Rise in EPS, Revenue for Half Year FY24, Beats Estimates MT
Chart CSL Limited
More charts
CSL Limited is an Australia-based biotechnology company. The Company’s areas of focus include rare and serious diseases, influenza vaccines and iron deficiency and nephrology. The Company’s segments include CSL Behring, CSL Seqirus and CSL Vifor. The CSL Behring segment manufactures, markets and distributes plasma products, gene therapies and recombinants. The CSL Seqirus segment manufactures, markets and distributes predominantly influenza related products and provides pandemic services to governments. The CSL Vifor segment manufactures, markets and distributes products in the therapeutic areas of iron deficiency and nephrology. Its CSL Plasma operates plasma collection networks, with more than 325 plasma collection centers in the United States, Europe and China. The Company operates in Australia, the United States, Germany, the United Kingdom, Switzerland and China. Its products include Respreeza, Zemaira, HAEGARDA, KCENTRA, Hepatitis B, Evogam and others.
Calendar
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
A-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
16
Last Close Price
173.5 USD
Average target price
199.5 USD
Spread / Average Target
+14.99%
Consensus
  1. Stock Market
  2. Equities
  3. CSL Stock
  4. News CSL Limited
  5. CSL Prices $4 Billion of Bonds in US Debt Market